Researchers from Columbia University Medical Center (CUMC) have found that, for many patients, an initial diagnosis of “acute kidney injury” may have been inaccurate. Their finding, based on an analysis of patient records, suggests that the current method of assessing kidney function may be misleading during the initial evaluation of a patient.
The study, which also identified sets of biomarkers in mouse models that could potentially detect kidney damage more reliably, was published online in the December 2016 issue of the Journal of the American Society of Nephrology.
In a related Comment published today in The Lancet, Jonathan Barasch, MD, PhD, professor of medicine and pathology and cell biology at Columbia, and colleagues Drs. Joseph Bonventre (Harvard Medical School, Brigham and Women’s Hospital) and Richard Zager (University of Washington Medicine) explain that the blood test, which measures serum creatinine—a waste product that is removed by the kidneys and excreted in urine—only offers a snapshot of the kidney’s function at a given moment, which can vary depending on individual factors such as body size and muscle mass.
Each year, an estimated 5 percent to 7 percent of patients admitted to hospitals in the United States. and 30 percent to 50 percent of patients in critical or intensive care settings are diagnosed with acute kidney injury (AKI). However, the true degree of injury cannot be known for many days because creatinine tests only provide a retrospective look at the kidney’s response to possible injury. In addition, the blood test can register “positive” for AKI even when the kidney may not have been injured.
“Nephrologists are trained to evaluate a constellation of factors in determining whether or not a patient has a condition that may temporarily affect kidney function, such as dehydration or heart failure, and to distinguish these temporary conditions from true kidney cell damage,” said Dr. Barasch, one of the authors of the study. “But in a busy, time-pressured setting such as the emergency room or intensive care unit, doctors rely to a greater extent on the blood test used as a proxy for measuring kidney function in order to make an immediate diagnosis. Unfortunately, the initial creatinine tests can lead to misdiagnosis and inappropriate treatment.”
Misdiagnoses appear to be common, according to the researchers’ review of the electronic health records of 3.8 million emergency and intensive care patients. The researchers detected more than 61,000 diagnoses of AKI, as defined by rising creatinine level. Within three days, however, 73 percent of patients with an AKI diagnosis had creatinine levels that returned to normal, suggesting that many of these patients may not have had kidney damage.
“Previous studies have shown that a small but persistent change in creatinine level is a greater predictor of morbidity and mortality than a large, but transient, increase,” said Dr. Barasch. “But because the course of creatinine cannot be known when first seeing a patient, it is possible to deliver the wrong diagnosis. An initial misdiagnosis can lead to mistreatment, with potentially dangerous consequences.”
Failure to treat dehydration can quickly lead to irreversible kidney damage. In patients who already have kidney damage, rehydration therapy can cause pulmonary edema, a buildup of fluid in the lungs.
In the study, the investigators sought a more precise and timely method of identifying patients with kidney damage. They looked for biomarkers to distinguish between kidney damage and a transient condition, both of which activate a rise in the creatinine blood test. The researchers performed genomic analyses of mice with kidney damage and those with dehydration and a similar rise in creatinine levels. Their analyses revealed more than a thousand biomarkers (proteins) distinguishing these two conditions, with minimal overlap.
“Our ongoing studies may help to determine if these biomarkers can be deployed in the emergency or intensive care setting to improve the initial diagnosis and treatment plan when kidney damage is in doubt,” said Katherine Xu, a PhD candidate in Columbia’s Institute of Human Nutrition and lead author of the study.
The paper is titled “Unique Transcriptional Programs Identify Subtypes of AKI.” Additional authors included Paul Rosenstiel (CUMC, New York, NY), Neal Paragas (University of Washington, Seattle, WA), Christian Hinze (Max Delbrück Center for Molecular Medicine, Berlin, Germany), Xiabo Gao (Icahn School of Medicine at Mount Sinai, New York, NY), Tian Huai Shen (CUMC), Max Werth (CUMC), Catherine Forster (Cincinnati Children’s Hospital Medical Center, Cincinnati, OH), Rong Deng (CUMC), Efrat Bruck (CUMC), Roger W. Boles (CUMC), Alexandra Tornato (CUMC), Tejashree Gopal (CUMC), Madison Jones (CUMC), Justin Konig (CUMC), Jacob Stauber (CUMC), Vivette D’Agati (CUMC), Hediye Erdjument-Bromage (New York University Langone Medical Center, New York, NY), Subodh Saggi (State Universtity of New York Downstate Medical Center, Brooklyn, NY), Gebhard Wagener (CUMC), Kai M. Schmidt-Ott (Max Delbrück Center for Molecular Medicine), Nicholas Tatonetti (CUMC), Paul Tempst (Memorial Sloan Kettering Cancer Center, New York, NY), Juan A. Oliver (CUMC), and Paolo Guarnieri (CUMC).
The Lancet Comment is titled, “Acute Kidney Injury: A Problem of Definition.” Authors include J. V. Bonventre (Harvard Medical School, Boston), Richard Zager (Fred Hutchinson Cancer Center and the University of Washington, Seattle), and Jonathan Barasch (CUMC).
Dr. Barasch is a co-inventor on a number of patent applications for the use of biomarkers.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. The campus that Columbia University Medical Center shares with its hospital partner, NewYork-Presbyterian, is now called the Columbia University Irving Medical Center. For more information, visit cumc.columbia.edu or columbiadoctors.org